Literature DB >> 10562305

Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

M Dalod1, M Dupuis, J C Deschemin, C Goujard, C Deveau, L Meyer, N Ngo, C Rouzioux, J G Guillet, J F Delfraissy, M Sinet, A Venet.   

Abstract

HIV-specific CD8(+) T cells play a major role in the control of virus during HIV primary infection (PI) but do not completely prevent viral replication. We used IFN-gamma enzyme-linked immunospot assay and intracellular staining to characterize the ex vivo CD8(+) T-cell responses to a large variety of HIV epitopic peptides in 24 subjects with early HIV PI. We observed HIV-specific responses in 71% of subjects. Gag and Nef peptides were more frequently recognized than Env and Pol peptides. The number of peptides recognized was low (median 2, range 0-6). In contrast, a much broader response was observed in 30 asymptomatic subjects with chronic infection: all were responders with a median of 5 peptides recognized (range 1-13). The frequency of HIV-specific CD8(+) T cells among PBMC for a given peptide was of the same order of magnitude in both groups. The proportion of HIV-specific CD8(+)CD28(-) terminally differentiated T cells was much lower in PI than at the chronic stage of infection. The weakness of the immune response during HIV PI could partially account for the failure to control HIV. These findings have potential importance for defining immunotherapeutic strategies and establishing the goals for effective vaccination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562305      PMCID: PMC409838          DOI: 10.1172/JCI7162

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

2.  Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity.

Authors:  S Fiorentino; M Dalod; D Olive; J G Guillet; E Gomard
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection.

Authors:  S Lamhamedi-Cherradi; B Culmann-Penciolelli; B Guy; T D Ly; C Goujard; J G Guillet; E Gomard
Journal:  AIDS       Date:  1995-05       Impact factor: 4.177

4.  An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status.

Authors:  A L Landay; C E Mackewicz; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1993-10

5.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.

Authors:  A Jaye; A F Magnusen; A D Sadiq; T Corrah; H C Whittle
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

7.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.

Authors:  J W Mellors; L A Kingsley; C R Rinaldo; J A Todd; B S Hoo; R P Kokka; P Gupta
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

9.  Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection.

Authors:  H Choremi-Papadopoulou; V Viglis; P Gargalianos; T Kordossis; A Iniotaki-Theodoraki; J Kosmidis
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

10.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.

Authors:  O Schwartz; V Maréchal; S Le Gall; F Lemonnier; J M Heard
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  52 in total

1.  Changes in function of HIV-specific T-cell responses with increasing time from infection.

Authors:  Michel L Ndongala; Philomena Kamya; Salix Boulet; Yoav Peretz; Danielle Rouleau; Cécile Tremblay; Roger Leblanc; Pierre Côté; Jean-Guy Baril; RéJean Thomas; Sylvie Vézina; Mohamed R Boulassel; Jean-Pierre Routy; Rafick P Sékaly; Nicole F Bernard
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

Review 2.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation.

Authors:  Judith Racape; Francine Connan; Johan Hoebeke; Jeannine Choppin; Jean-Gérard Guillet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol.

Authors:  A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

5.  Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.

Authors:  Dirk Meyer-Olson; Kristen W Brady; Melissa T Bartman; Kristin M O'Sullivan; Brenna C Simons; Joseph A Conrad; Coley B Duncan; Shelly Lorey; Atif Siddique; Rika Draenert; Marylyn Addo; Marcus Altfeld; Eric Rosenberg; Todd M Allen; Bruce D Walker; Spyros A Kalams
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

6.  Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.

Authors:  W M Cohen; A Bianco; F Connan; L Camoin; M Dalod; G Lauvau; E Ferriès; B Culmann-Penciolelli; P M van Endert; J P Briand; J Choppin; J G Guillet
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes.

Authors:  Flavien Bernardin; Denice Kong; Lorraine Peddada; Lee Ann Baxter-Lowe; Eric Delwart
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

10.  Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes.

Authors:  Concepción Marañón; Jean-François Desoutter; Guillaume Hoeffel; William Cohen; Daniel Hanau; Anne Hosmalin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.